Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11129889-B2
Publication Date
2021-09-28
Expiration Date
Abstract
Provided herein are recombinant nucleic acid sequences derived from the C-terminal domain of the HIV-1 gp41 protein, and more specifically compositions and methods for using these epitopes to develop vaccine protection against HIV. Also provided here are monoclonal antibodies that specifically bind to these recombinant nucleic acid sequences derived from the C-terminal domain of the HIV-1 gp41 protein.
Core Innovation
The invention provides recombinant peptide sequences for vaccine compositions effective against Human Immunodeficiency Virus-1 (HIV-1) infection, where the peptides derive from the Kennedy loop of the HIV-1 gp41 C-terminal domain and are conformationally constrained by two or more terminal cysteine residues. The peptides have at least 90% or more sequence identity to the C-terminal domain of the Kennedy loop, with the C-terminal domain defined as positions 43 to 66 and specified by one of multiple peptide sequences (SEQ ID NOs: 31 to 39).
The invention further provides recombinant peptide sequences for vaccine compositions effective against HIV-1 infection, where the peptides derive from the Kennedy loop of the HIV-1 gp41 N-terminal domain and are conformationally constrained by two or more terminal cysteine residues. The peptides have at least 90% or more sequence identity to the N-terminal domain of the Kennedy loop, with the N-terminal domain defined as positions 27 to 44 and specified by one of multiple peptide sequences (SEQ ID NOs: 31 to 39).
The approach centers on Kennedy loop epitopes from HIV-1 gp41 and on conformational constraint using terminal cysteine residues, while maintaining high sequence identity to the defined gp41 Kennedy loop domains. The problem addressed is effective vaccination against HIV-1 infection.
Claims Coverage
The partial claims provided include two independent claims. Each independent claim defines a vaccine composition effective against HIV-1 infection based on a conformationally constrained recombinant Kennedy loop peptide with at least 90% sequence identity to a specified gp41 Kennedy loop domain.
Conformationally constrained C-terminal Kennedy loop recombinant peptide vaccine
A vaccine composition effective against HIV-1 infection comprising a recombinant peptide sequence having at least 90% or more sequence identity to the C-terminal domain of the Kennedy loop of a HIV-1 gp41 protein, the peptide being conformationally constrained by two or more terminal cysteine residues, wherein the C-terminal domain is positions 43 to 66 and corresponds to one of the listed C-terminal domain sequences (SEQ ID NO: 31 to 39).
Conformationally constrained N-terminal Kennedy loop recombinant peptide vaccine
A vaccine composition effective against HIV-1 infection comprising a recombinant peptide sequence having at least 90% or more sequence identity to the N-terminal domain of the Kennedy loop of a HIV-1 gp41 protein, the peptide being conformationally constrained by two or more terminal cysteine residues, wherein the N-terminal domain is positions 27 to 44 and corresponds to one of the listed N-terminal domain sequences (SEQ ID NO: 31 to 39).
Across the two independent claims, the core claim coverage is a vaccine composition effective against HIV-1 infection that includes a recombinant Kennedy loop peptide from HIV-1 gp41, constrained by two or more terminal cysteine residues and maintaining at least 90% sequence identity, with the domain location fixed to either positions 43 to 66 (C-terminal) or positions 27 to 44 (N-terminal) and selected from the provided SEQ ID NO sequences.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?